Psoriatic arthritis is a chronic inflammatory arthropathy associated with cutaneous psoriasis.
It is a progressive disease with asymmetric joint distribution pattern and rheumatoid factor is negative.
It can develop at any time including childhood but most often occurs between 30-50 years old.
Symptoms may range from mild to very severe.

Psoriatic%20arthritis Treatment

Principles of Therapy

  • Treatment should be initiated once psoriatic arthritis is diagnosed in order to alleviate the manifestations, prevent structural damage, delay disease progression, & maximize the quality of life


Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

  • Provide good short-term symptomatic relief for patients w/ mild psoriatic arthritis
  • Do not inhibit the development of structural joint damage
  • Lowest effective dose of NSAID or COX-2 selective inhibitor should be given for the shortest duration in controlling symptoms due to the potential cardiotoxicity


  • Good symptomatic relief for mild psoriatic arthritis but corticosteroids cannot inhibit joint damage
  • Intra-articular corticosteroids are used for persistent synovitis (eg monoarthritis or oligoarthritis) or for bridging therapy while waiting for the systemic treatment to take effect
    • Intra-articular corticosteroids can be used when only a few joints are involved
  • Studies showed no evidence to support the use of systemic corticosteroids in patients w/ peripheral psoriatic arthritis

Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

  • Used for patients w/ moderate to severe psoriatic arthritis that is more extensive or aggressive disease, requiring more potent treatment
  • Choice of DMARD should be based on patient preference, severity of joint & skin diseases, efficacy, comorbidities, risks of adverse effects, cost of medication & monitoring
  • DMARD failure is considered if at least 1 DMARD has failed individually or in combination in an adequate therapeutic trial (treatment for ≥3 mth of w/c 2 mth is at standard target dose)


  • A treatment option for patients w/ active psoriatic arthritis
  • Studies have shown that patients showed less joint tenderness & swelling & better physical function while on Apremilast therapy
  • A cyclic adenoside monophosphate (cAMP)-specific phosphodiesterase type-4 (PDE-4) inhibitor that acts by suppressing pro-inflammatory mediators


  • Primary DMARD in psoriatic arthritis
  • First-line therapy for patients w/ moderate to severe active psoriatic arthritis
  • Effective in treating skin & joint involvement
  • Studies showed reduction in joint swelling, tenderness & erythrocyte sedimentation rate
    • Patients given w/ Methotrexate also showed superior physician assessment of arthritis activity compared to the placebo group


  • Selectively inhibits pyrimidine synthesis that targets activated T-lymphocytes
  • Recommended for treatment of active peripheral psoriatic arthritis


  • Used as an alternative in treating peripheral psoriatic arthritis
  • Has modest efficacy in patients w/ psoriatic arthritis
  • There were statistically significant positive effects on patient & physician global assessment of disease activity


  • May be considered in patients w/ active arthritis unresponsive to at least 2 conventional DMARDs
  • Use is limited because of toxicity issues

Other Disease-Modifying Anti-Rheumatic Drugs

  • Further studies are needed to prove efficacy of gold salts, Azathioprine, & d-Penicillamine for the treatment of psoriatic arthritis

Tumor Necrosis Factor (TNF) Inhibitors

  • Inhibit the pro-inflammatory cytokine involved in inflammation of the skin, synovium & joint fluid
  • Considered also as first-line treatment of moderate to severe active psoriatic arthritis
  • Recommended for treatment of active psoriatic arthritis in patients who are unresponsive or intolerant to at least 2 DMARDs or 1 DMARD w/ poor prognostic factors
  • More expensive compared w/ DMARDs but more cost-effective when used for a long period
  • Provide the following long-term benefits:
    • Decreased need for joint replacement surgery
    • Reduced demands on medical, nursing, & therapy services
    • Reduced needs for other medicines
    • Decreased demands on social services & careers
    • Improved quality of life
    • Increased probability of maintaining work
    • Increased life expectancy
  • TNF inhibitors have equal efficacy & similar adverse reactions
  • Choice of TNF blocker to use is individualized, taking into account the degree & severity of skin involvement
    • Other factors to consider are cost, patient preference, & physician preference 
  • Most clinicians use the combination of TNF inhibitor & Methotrexate as the standard care for the treatment of psoriatic arthritis
  • FDA warns physicians & the public of reports on the occurrence of hepatosplenic T-cell lymphoma, a rare malignancy, in patients receiving TNF inhibitors (eg Adalimumab, Etanercept, Golimumab)


  • Effective in the treatment of moderate to severe peripheral psoriatic arthritis
  • Studies showed significant benefits such as better response rates, decreased radiographic progression of hand & foot joint disease & improvement in disability


  • Effective in treating moderate to severe peripheral psoriatic arthritis
  • Studies showed improvement in signs & symptoms such as decrease in number of tender joints, swollen joints, & morning stiffness
    • Also noted are decreased C-reactive protein levels, inhibition of radiographic disease progression & better physician & patient global ratings


  • Recommended for the treatment of active & progressive psoriatic arthritis
  • Studies showed statistically significant improvements in joint disease as compared to placebo


  • Effective in moderate to severe peripheral psoriatic arthritis
  • Studies showed better response rates, decreased dactylitis & enthesitis, & inhibition of radiographic disease progression


  • A human monoclonal antibody that targets IL-12 & IL-23
  • Recently approved by the FDA for the treatment of adult patients w/ active psoriatic arthritis
  • May be used alone or in combination w/ Methotrexate
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Jairia Dela Cruz, 23 hours ago
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.
5 days ago
Daily intake of cow’s milk formula in early life helps prevent the development of cow’s milk allergy later on without competing with breastfeeding, a recent study has found.